论文部分内容阅读
目的观察参芪注射液对重组人血管内皮抑素(恩度)联合化疗所致心脏毒性的保护作用。方法将48例经病理确诊的Ⅲ、Ⅳ期恶性肿瘤患者,分成治疗组(在恩度联合化疗基础上加参芪注射液)和对照组(恩度联合化疗),观察两组治疗前后左室射血分数(LVEF)、心电图(EKG)、心肌酶谱、血浆肌钙蛋白Ⅰ(troponinⅠ)的变化和心血管不良反应。结果对照组LVEF下降而治疗组LVEF升高,组间差异有显著性(P<0.05);对照组心电图异常发生率(41.66%)有高于治疗组(25.00%)的趋势(P>0.05);两组心肌酶升高及心血管不良反应相关症状比较无显著性差异(P>0.05)。治疗组的生活质量提高(P<0.05);两组近期疗效无显著性差异(P>0.05)。结论参芪注射液对恩度联合化疗的心脏不良反应有一定保护作用,主要表现为维持左室射血功能,同时不影响疗效。
Objective To observe the protective effects of Shenqi injection on cardiotoxicity induced by recombinant human endostatin (Endostar) in combination with chemotherapy. Methods Forty-eight patients with pathologically confirmed stage III and IV malignant tumors were divided into treatment group (with Shenqi injection on the basis of Endostar combined chemotherapy) and control group (Endo combined with chemotherapy). The changes of left ventricular (LVEF), electrocardiogram (EKG), myocardial enzymes, plasma troponin Ⅰ and cardiovascular adverse reactions. Results The LVEF in the control group decreased and the LVEF in the treatment group increased significantly (P <0.05). The incidence of electrocardiogram abnormality in the control group (41.66%) was higher than that in the treatment group (25.00%) (P> 0.05) There was no significant difference between the two groups in the correlation between myocardial enzymes and cardiovascular adverse reactions (P> 0.05). The quality of life of the treatment group was improved (P <0.05). There was no significant difference between the two groups in the short term efficacy (P> 0.05). Conclusion Shenqi injection has a protective effect on cardiac adverse reactions of entecavir combined with chemotherapy, mainly for maintaining left ventricular ejection function without affecting the curative effect.